Quantcast

Latest DelMar Pharmaceuticals Inc. Stories

2014-04-07 12:33:26

New data demonstrates VAL-083 is superior to standard platinum-based chemotherapy in an established in vivo model of non-small cell lung cancer (NSCLC) VANCOUVER, British Columbia, MENLO PARK, Calif. and SAN DIEGO, April 7, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014...

2014-04-02 12:32:51

New data demonstrates VAL-083 has promise as a potential treatment of non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM) VANCOUVER, British Columbia and MENLO PARK, Calif., April 2, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the Company would present two abstracts at the 105th Annual Meeting of the American Association for Cancer Research (AACR), which is being held April 5-9, 2014, in San Diego. The Company...

2014-03-20 08:29:42

VANCOUVER, British Columbia and MENLO PARK, Calif., March 20, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") provided an update as of the quarter ended December 31, 2013 and a summary of progress toward the Company's goals for the year. DelMar also announced an investor conference call to take place today at 1 pm EDT. Details and log-in information will be posted on the website at www.delmarpharma.com in advance of the call....

2014-03-06 08:29:14

NEW YORK, March 6, 2014 /PRNewswire/ -- SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The note is focuses on DelMar Pharmaceuticals...

2014-03-04 08:31:55

VANCOUVER, British Columbia and MENLO PARK, Calif., March 4, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") a pharmaceutical company developing its VAL-083 chemotherapy as a potential new therapy for glioblastoma multiforme, today announced that Jeffrey A. Bacha, President and CEO of DelMar Pharmaceuticals, Inc., will present at the upcoming 26(th) Annual ROTH Capital Conference. Mr. Bacha will make a corporate presentation to...

2014-02-26 08:28:38

Interim clinical data to be presented at American Association of Cancer Research (AACR) Annual Meeting on April 9, 2014 VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 26, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") provided an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM). DelMar has completed enrollment of VAL-083 dose Cohort 5 and advanced to Cohort 6. DelMar...

2014-01-13 08:30:16

NEW YORK, Jan. 13, 2014 /PRNewswire/ -- SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. "DelMar's lead drug candidate, VAL-083, is a...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related